Daniel Ilzarbe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Ilzarbe has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ernesto Magallón-Neri
Departamento de Psicología Clínica y Psicobiología. 2017SGR1681 (GEIMAC). Facultad de Psicología. Universidad de Barcelona, Barcelona
1 shared publication Javier Goti
Servicio de Psiquiatría y Psicología, IMQ-AMSA, Bilbao
1 shared publication- Josefina Castro-Fornieles
Department of Child and Adolescent Psychiatry and Psychology, Institut Clínic de Neurociències, Hospital Clinic of Barcelona, 08036 Barcelona, Spain
1 shared publication - Rosa Díaz-Hurtado
Servicio de Psiquiatría y Psicología Infanto-Juvenil. Instituto de Neurociencias. Hospital Clínic de Barcelona
1 shared publication - Sandra Mateus-Gómez
Departamento de Psicología Clínica y Psicobiología. 2017SGR1681 (GEIMAC). Facultad de Psicología. Universidad de Barcelona, Barcelona
1 shared publication
Latest Publications
- Open Access
- 1 December 2024
- Published by Socidrogalcohol in Adicciones
- Vol. 36 (4) , 399-414
Integrated vs. parallel treatment in adolescents with substance use and comorbid disorders: A randomized trial
Integrated treatments are often recommended for adolescents with substance use disorders (SUD) and comorbid pathologies. This study aims to compare the effectiveness of two different intervention programs (integrated and parallel) and to investigate treatment outcome predictors. Seventy-five adolescents (13-17 years old) with substance use and comorbid disorders referred to our outpatient program were randomized to integrated (n = 33) or parallel (n = 32) treatment groups. Their sociodemographic variables, psychopathology, substance use problems, and global functioning were assessed at baseline and 12 months after treatment initiation. Both treatments were associated with positive pre-post changes in several outcome variables (severity of school, family, and psychiatric problems; global functioning; and stage of change). Integrated treatment showed better outcome on adherence (χ2 = 14.328; p > .001) and a composite global measure based on the severity of drug-related problems (χ2 = 8.833, p = .003). Following an adaptive treatment strategy, we offered patients who dropped out of parallel treatment (n = 12) the possibility of entering integrated treatment. Eleven of them accepted and constituted a third comparison group (parallel-to-integrated). Multivariate logistic regression analysis showed that the likelihood of a positive global treatment outcome increased with integrated or parallel-to-integrated treatment, internalizing or mixed comorbid disorders, older age, and fewer legal issues. Integrated treatment showed better adherence and global treatment outcomes than parallel treatment in adolescent patients with dual disorders. Older age and fewer legal issues were also related to a positive global treatment outcome.
- 1 December 2024
- Published by Socidrogalcohol in Adicciones
- Vol. 36 (4) , 399-414
Open AccessIntegrated vs. parallel treatment in adolescents with substance use and comorbid disorders: A randomized trial
Integrated treatments are often recommended for adolescents with substance use disorders (SUD) and comorbid pathologies. This study aims to compare the effectiveness of two different intervention programs (integrated and parallel) and to investigate treatment outcome predictors. Seventy-five adolescents (13-17 years old) with substance use and comorbid disorders referred to our outpatient program were randomized to integrated (n = 33) or parallel (n = 32) treatment groups. Their sociodemographic variables, psychopathology, substance use problems, and global functioning were assessed at baseline and 12 months after treatment initiation. Both treatments were associated with positive pre-post changes in several outcome variables (severity of school, family, and psychiatric problems; global functioning; and stage of change). Integrated treatment showed better outcome on adherence (χ2 = 14.328; p > .001) and a composite global measure based on the severity of drug-related problems (χ2 = 8.833, p = .003). Following an adaptive treatment strategy, we offered patients who dropped out of parallel treatment (n = 12) the possibility of entering integrated treatment. Eleven of them accepted and constituted a third comparison group (parallel-to-integrated). Multivariate logistic regression analysis showed that the likelihood of a positive global treatment outcome increased with integrated or parallel-to-integrated treatment, internalizing or mixed comorbid disorders, older age, and fewer legal issues. Integrated treatment showed better adherence and global treatment outcomes than parallel treatment in adolescent patients with dual disorders. Older age and fewer legal issues were also related to a positive global treatment outcome.